This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Amazon, Intel & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Intel (INTC) and Eli Lilly (LLY).
Merck's Keytruda Under FDA Review for Advanced Melanoma
by Zacks Equity Research
Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.
Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies
by Zacks Equity Research
Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.
Merck (MRK) Presents New Data from Januvia Diabetes Studies
by Zacks Equity Research
Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.
Lilly Wins Favorable Ruling From U.S. Court in Alimta Row
by Zacks Equity Research
Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.
Merck (MRK) Stock Up So Far This Year on Keytruda Strength
by Zacks Equity Research
Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Incyte (INCY) Announces Positive Results on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.
Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
LLY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is Eli Lilly and Company (LLY) Outperforming Other Medical Stocks This Year?
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
by Zacks Equity Research
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
by Zacks Equity Research
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
by Zacks Equity Research
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) to sell its LifeScan diabetes device unit to Platinum Equity.
Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
by Zacks Equity Research
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
by Zacks Equity Research
Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.
Alzheimer's Research Stumbles Again: What's the Road Ahead?
by Kinjel Shah
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.
Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
by Zacks Equity Research
AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.
Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe
by Zacks Equity Research
Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space
by Indrajit Bandyopadhyay
Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
J&J Receives Buyout Offer for Sterilization Products Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.